ClinicalTrials.gg
Not yet recruitingNCT07670078Updated Aug 25, 2026

Comparıson of Analgesıc Effıcacy of Dıfferent Volumes of Serratus Posterior Superıor Intercostal Plane Block After Modıfıed Radıcal Mastectomy Surgery

An interventional study of Serratus Posterior Superior Intercostal Plane (SPSIP) block 40 ml of 0.1875% bupivacaine and Serratus Posterior Superior Intercostal Plane (SPSIP) 50 ml of 0.15% bupivacaine in Modified Radical Mastectomy, Post Operative Pain, Acute and Facial Plane Blocks, sponsored by Cumhuriyet University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Cumhuriyet University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The aim of researchers is to compare the effects of three different local anesthetic concentrations and volumes on opioid consumption, postoperative analgesic efficacy, and pain scores during ultrasound-guided SPSIP blocks in patients undergoing modified radical mastectomy. Additionally, we aim to map and identify the dermatomal areas where different concentrations and volumes of SPSIP blocks provide analgesia.

Read the detailed description

The researchers' hypothesis is that a lower concentration but higher volume of SPSIP block could provide similar analgesic efficacy to a higher concentration and lower volume block, while also improving the safety profile in terms of local anesthetic systemic toxicity by reducing the total local anesthetic load. In other words, we believe that using less than the 0.25% bupivacaine used in previous studies on this block could provide similar analgesic efficacy. This is because, in fascial plane blocks, separating the fascia is as important a technique as the local anesthetic administered. Facial plane blocks are volume-dependent blocks.

The Modified Aldrete scoring system is a routine assessment performed in our clinic's postoperative recovery room to determine whether a patient has recovered. Patients with an NRS score of 4 or higher, despite routine analgesia, will receive 50 mg tramadol hydrochloride as a rescue analgesic, administered intravenously over 30 minutes in 150 ml of saline solution.

02

Conditions studied

  • Modified Radical Mastectomy
  • Post Operative Pain, Acute
  • Facial Plane Blocks

Browse trials for

Keywords

  • postoperative pain
  • regional anesthesia
  • Modified radical mastectomy
  • opioid free analgesia
  • facial plan block
  • serratus posterior superior intercostal plane block
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 90 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Cumhuriyet University is the lead sponsor of 133 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study included adult patients over 18 years of age who underwent modified radical mastectomy under general anesthesia and were classified in risk groups I-II-III according to the (ASA) risk classification.

Exclusion criteria

Exclusion Criteria:

  • patients with coagulopathy,
  • patients with signs of infection at the block application site,
  • patients with
  • patients with known allergies to any of the study drugs,
  • patients with ineffective block
  • patients who could not cooperate during postoperative pain assessment
  • patients who wanted to withdraw from the study,
  • patients with alcohol and drug addiction,
  • patients with musculoskeletal abnormalities
  • patients with kidney and liver failure
  • patients with obesity (body mass ≥ 35 kg/m2)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    30 ml of 0.25% Bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 30 ml of 0.25% bupivacaine (15 ml of the drug + 15 ml of isotonic solution).

    Procedure: Serratus Posterior Superior Intercostal Plane (SPSIP) 30 ml of 0.25% bupivacaine

  • Active comparator
    40 ml of 0.1875% Bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 40 ml of 0.1875% bupivacaine (15 ml of the drug + 25 ml of isotonic solution).

    Procedure: Serratus Posterior Superior Intercostal Plane (SPSIP) block 40 ml of 0.1875% bupivacaine

  • Active comparator
    50 ml of 0.15% bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 50 ml of 0.15% bupivacaine (15 ml of the drug + 35 ml of isotonic solution).

    Procedure: Serratus Posterior Superior Intercostal Plane (SPSIP) 50 ml of 0.15% bupivacaine

Interventions

  • ProcedureSerratus Posterior Superior Intercostal Plane (SPSIP) block 40 ml of 0.1875% bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 40 ml of 0.1875% bupivacaine (15 ml of the drug + 25 ml of isotonic solution).

  • ProcedureSerratus Posterior Superior Intercostal Plane (SPSIP) 50 ml of 0.15% bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 50 ml of 0.15% bupivacaine (15 ml of the drug + 35 ml of isotonic solution).

  • ProcedureSerratus Posterior Superior Intercostal Plane (SPSIP) 30 ml of 0.25% bupivacaine

    A Serratus Posterior Superior Intercostal Plane (SPSIP) block will be performed using 30 ml of 0.25% bupivacaine (15 ml of the drug + 15 ml of isotonic solution).

06

What researchers measure

Primary outcomes

  1. Total tramadol consumption

    Postoperative total analgesic need was recorded as "milligram" in unit.

    Time frame: Postoperative 24 hours

Secondary outcomes

  1. Dermatome Area

    Thirty minutes after the block procedure, we will perform a pinprick test by inserting a sterile needle from the tip of the syringe into the patient's skin and recording the areas where skin analgesia has developed.

    Time frame: 30th minute after the block

  2. Numeric Rating Scale (NRS) Scores

    Description: Numerical rating scale is used for pain assessment. The scores of the numerical rating scale changes between 0 to 10 points. 10 points mean "the most severe pain

    Time frame: Postoperative 24 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07670078
Responsible party
Oguz Gundogdu (ASSOCIATE PROFESSOR, Cumhuriyet University) — Principal investigator
First posted
Jun 26, 2026
Start date
Aug 25, 2026 (estimated)
Primary completion
Aug 25, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

OĞUZ GÜNDOĞDU
Contact
oguzgundogdu@cumhuriyet.edu.tr
+905545945469

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion